Evidence map›Paper›PMID 37601873›Full record

ArticleEJHaem2023

Direct infiltration of clonal plasma cells causes renal insufficiency in patients with monoclonal gammopathy of undetermined significance.

Ryosuke Naka, Yoshimitsu Shimomura, Madoka Kanda-Kato, Nobuhiro Hiramoto, Shigeo Hara, Takayuki Ishikawa

Open access · diamondAbstract readCase Reports
In one paragraph

Article in EJHaem, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Ryosuke NakaDepartment of Hematology Kobe City Hospital Organization Kobe City Medical Center General Hospital Kobe Japan.
Yoshimitsu ShimomuraDepartment of Hematology Kobe City Hospital Organization Kobe City Medical Center General Hospital Kobe Japan.ORCID https://orcid.org/0000-0003-1018-9508
Madoka Kanda-KatoDepartment of Hematology Kobe City Hospital Organization Kobe City Medical Center General Hospital Kobe Japan.
Nobuhiro HiramotoDepartment of Hematology Kobe City Hospital Organization Kobe City Medical Center General Hospital Kobe Japan.
Shigeo HaraDepartment of Diagnostic Pathology Kobe City Hospital Organization Kobe City Medical Center General Hospital Kobe Japan.
Takayuki IshikawaDepartment of Hematology Kobe City Hospital Organization Kobe City Medical Center General Hospital Kobe Japan.
Kobe City Medical Center General Hospital · JPOsaka University of Economics · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monoclonal gammopathy of undetermined significance (MGUS) is a benign but precancerous condition that can progress to multiple myeloma. Patients with MGUS are typically monitored closely for signs of disease progression, but in some cases, they may also develop renal insufficiency, a condition known as monoclonal gammopathy of renal significance (MGRS). In MGRS, M-protein secreted by a nonmalignant or premalignant cell clone triggers renal damage by definition. Herein, we report a case of a 66-year-old Asian male with MGUS complicated by renal insufficiency. A kidney biopsy showed no evidence of renal injury mediated by M-protein; instead, the direct infiltration of clonal cells into renal tissues was observed. Although five similar cases have been previously reported, our case is unique in that the involvement of clonal cells was directly confirmed by fluorescence in situ hybridization. Our findings suggest the need to consider a novel disease concept, as this phenomenon appears to be reproduced.

Identifiers

PMID37601873
PMCPMC10435693
OpenAlexW4382055139

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.